The Role of Factor VII in Haemostasis: Infusion Studies of Factor VIIa in a Canine Model of Factor VIII Deficiency

Summary

The role of factor VIIa in haemostasis has been studied using a canine model of factor VIII deficiency. Highly purified human factor VIIa was administered to dogs at a dosage of 0.5 μg/kg. At selected times pre- and post-infusion, haemostasis was evaluated by the cuticle bleeding time. Plasma was collected for the assay of various parameters, including fibrinopeptide A (FPA) as a marker for thrombin generation in vivo. Factor VIIa infusion resulted in a 6-fold increase of factor VII clotting activity with z t_1/2 of 2 h. FPA levels which were 1.4 ng/ml before infusion, did not increase significantly in haemophilic dogs. In normal dogs, however, FPA levels rose to a mean value of 190 ng/ml 30 min post-infusion. It appeared that thrombin generation by factor VIIa infusion had occurred mainly via the intrinsic, factor VIIIdependent pathway. In factor VIII-deficient dogs, factor VIIa infusion did not correct cuticle bleeding, but an inconsistent haemostatic effect was observed 15–30 min post-infusion. Similar results were obtained in haemophilic dogs with circulating antibodies against factor VIII. The haemostatic effectivity could not be improved by increasing the factor VIIa dosage up to 40-fold. Although these data suggest that the extrinsic, factor VIIdependent factor X activation provides only a minor pathway of thrombin generation in vivo, it is possible that the suboptimal haemostatic effect noted may be promoted in bleeding situations where tissue factor availability is less limited. As such, factor VIIa may prove useful in the treatment of haemophilia A patients with acquired inhibitors to factor VIII.

• References

• 1 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
• 2 Nemerson Y. The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 1966; 5: 601-608
• 3 Macfarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964; 202: 498-499
• 4 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312
• 5 Biggs R, Nossel HL. Tissue extract and the contact reaction in blood coagulation. Thromb Diath Haemorrh 1961; 6: 1-14
• 6 Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh 1965; (Suppl. 17) (Suppl.) 35-44
• 7 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
• 8 Nemerson Y, Zur M. Is hemophilia a disease of the tissue factor pathway of coagulation?. In: Progress in Clinical and Biological Research Vol 72 – Hemophilia and Hemostasis Mènachè D, Surgenor DM, Anderson H. (eds) Alan R Liss Inc; New York: 1981. pp 77-83
• 9 Østerud B, Rapaport SI. Activation of 125I-factor IX and ¹²⁵I-factor X: Effect of tissue factor and factor VII, factor Xa and thrombin. Scand J Haematol 1980; 24: 213-226
• 10 Morrison S, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63: 1338-1347
• 11 Wam-Cramer BJ, Bajaj SP. Intrinsic versus extrinsic coagulation: kinetic considerations. Biochem J 1986; 239: 757-762
• 12 Bom VJ J, van Hinsbergh VW M, Reinalda-Poot JH, Mohanlal RW, Bertina RM. Extrinsic activation of human coagulation factors IX and X on the endothelial surface. Thromb Haemostas 1987; 58: 522 (Abstr 1931)
• 13 Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353-1358
• 14 Stem DM, Nawroth P, Handley D, Kisiel W. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci USA 1985; 82: 2523-2527
• 15 Hedner U, Kisiel W. Use of human factor Vila in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841
• 16 Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-730
• 17 Pijnappels MI M, Briët E, van der Zwet GTh, Huisden R, van Tilburg NH, Eulderink F. Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemostas 1986; 55: 70-73
• 18 Denson KW E, Biggs R. Laboratory diagnosis, tests of clotting function and their standardization. In: Human Blood Coagulation, Haemostasis and Thrombosis Biggs R. (ed) Blackwell Scientific Publications; Oxford: 1976. pp 310-364
• 19 Thomson JM. Laboratory control of anticoagulant therapy. In: Blood Coagulation and Hemostasis Thomson JM. (ed) Churchill Livingstone; New York: 1980. pp 316-325
• 20 Leeksma OC, Meijer-Huizinga F, Stoepman-van Dalen EA, van Aken WG, van Mourik JA. Fibrinopeptide A in urine from patients with venous thromboembolism, disseminated intravascular coagulation and rheumatoid arthritis. Evidence for dephosphorylation and carboxyterminal degradation of the peptide by the kidney. Thromb Haemostas 1985; 54: 792-798
• 21 Seligsohn U, Østerud B, Rapaport SI. A coupled amidolytic assay for factor VTI: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978-988
• 22 Mertens K, Cupers R, van Wijngaarden A, Bertina RM. Binding of human blood-coagulation factors IXa and X to phospholipid membranes. Biochem J 1984; 223: 588-605
• 23 Mertens K, Bertina RM. The contribution of Ca²⁺ and phospholipids to the activation of human blood-coagulation factor X by activated factor IX. Biochem J 1984; 223: 607-615
• 24 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 25 Mertens K, Bertina RM. Pathways in the activation of human coagulation factor X. Biochem J 1980; 185: 647-658
• 26 Heystek J, Brummelhuis HG J, Krijnen HW. Contributions to the optimal use of human blood. II. The large-scale preparation of prothrombin complex. Vox Sang 1973; 25: 113-123
• 27 Tankersley DL, Alving BM, Finlayson JS. Preparation of β-XIIa (Hageman factor fragment) from human plasma. Thromb Res 1982; 25: 307-317
• 28 Mertens K, Giles AR, Brietz E. Assessment of factor VUI-bypassing activity of factor Vila in a canine model of hemophilia. Thromb Haemostas 1985; 54: 258 (Abstr 1529)
• 29 Giles AR, Tinlin S, Hoogendoom H, Fournel MA, Ng P, Pancham N. In vivo characterization of recombinant factor VIII in a canine model of hemophilia (factor VIII deficiency). Blood 1988; 72: 335-339
• 30 Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-497
• 31 O,Brien DP, Giles AR, Tate KM, Vehar GA. Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model. J Clin Invest 1988; 82: 206-11
• 32 Seligsohn U, Kasper CK, østerud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-37
• 33 Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor Vlla-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343
• 34 Kondo K, Kisiel W. Evidence that plasma lipoproteins inhibit the factor VII a-tissue factor complex by a different mechanism than extrinsic pathway inhibitor. Blood 1987; 70: 1947-1954
• 35 Mertens K, Bertina RM. Activation of human coagulation factor VIII by activated factor X, the common product of the intrinsic and extrinsic pathway of blood coagulation. Thromb Haemostas 1982; 47: 96-100
• 36 Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor Vila on the hemostatic defect in dogs with hemophilia A, hemophilia B and von Willebrand disease. Proc Natl Acad Sci USA 1988; 86: 1382-1386
• 37 Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985; 82: 8752-8756
• 38 Silverberg SA, Nemerson Y, Zur M. Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. J Biol Chem 1977; 252: 8481-8488
• 39 Bom VJ J, Bertina RM. The contributions of Ca²⁺, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990; 265: 327-336
• 40 Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-365
• 41 Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor Vila in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193
• 42 Macik BG, Hohneker J, Roberts HR, Griffin AM. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with high titer inhibitor. Am J Hematol 1989; 32: 232-234